Valeant revenue falls 8 percent

Canada's Valeant Pharmaceuticals reported a 7.8 percent drop in revenue, hurt by declines in volume and pricing of its generic and neurology products.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>